Regulators agree on Covid-19 vaccination adaptation plan

On June 30, representatives of regulatory authorities from around the world met to discuss the adaptation of the existing Covid-19 vaccines in response to new Omicron variants of concern.

Photo: Finn Frandsen

Despite the fact that evidence examined by regulatory authorities around the world and the World Health Organization (WHO) suggests that the first generation of Covid-19 vaccines still protects against serious illness, hospitalization and death, the organizations are keeping a close eye on new variants.

The Committee for Medicinal Products for Human use (CHMP) is therefore studying data from the new bivalent boosters, including those designed by Pfizer and Moderna, the EMA reveals on its website.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs